Clinical Trial

Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"

Study acronym: GMEDICO
Recruiting
View on ClinicalTrials.gov →
Summary
The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and oncologists who have developed a protocol for the monitoring and cardio-oncological management of patients treated for cancer. This unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined. Primary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology. Secondary objectives * To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data. * To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2018-04-03; most recent amendment 2022-09-19.
Status change: Not Yet Recruiting → Recruiting 2022-09-19
Trial Details
NCT Number NCT03492528
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Cardiovascular Prognosis
Enrollment 530 participants
Start Date 2019-07-05
Primary Completion 2027-04 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2022-09-21